These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 16908361)
1. Surgical Pearl: The use of a laboratory vortex for poly-L-lactic acid injection. Leonard AL; Hanke CW J Am Acad Dermatol; 2006 Sep; 55(3):511-2. PubMed ID: 16908361 [No Abstract] [Full Text] [Related]
2. Polylactic acid implants. A new smile for lipoatrophic faces? Boix V AIDS; 2003 Nov; 17(17):2533-5. PubMed ID: 14600527 [No Abstract] [Full Text] [Related]
3. Poly-l-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman. Burgess CM Dermatol Surg; 2009 May; 35(5):881-4. PubMed ID: 19389088 [No Abstract] [Full Text] [Related]
10. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Mest DR; Humble GM Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325 [TBL] [Abstract][Full Text] [Related]
11. Poly-L-lactic acid. Perry CM Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738 [TBL] [Abstract][Full Text] [Related]
12. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597 [TBL] [Abstract][Full Text] [Related]
13. The Use of Poly-L-Lactic Acid in the Gluteal Area. Mazzuco R; Sadick NS Dermatol Surg; 2016 Mar; 42(3):441-3. PubMed ID: 26859651 [No Abstract] [Full Text] [Related]
14. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. Moyle GJ; Brown S; Lysakova L; Barton SE HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632 [TBL] [Abstract][Full Text] [Related]
15. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Mest DR; Humble G Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585 [TBL] [Abstract][Full Text] [Related]
17. Soft tissue augmentation using sculptra. Humble G; Mest D Facial Plast Surg; 2004 May; 20(2):157-63. PubMed ID: 15643584 [TBL] [Abstract][Full Text] [Related]
18. A protocol for facial volume restoration with poly-L-lactic acid. Leonard AL; Hanke CW J Drugs Dermatol; 2006 Oct; 5(9):872-7. PubMed ID: 17039653 [TBL] [Abstract][Full Text] [Related]
19. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Mest DR; Humble GM Aesthetic Plast Surg; 2009 Jul; 33(4):654-6. PubMed ID: 18704558 [TBL] [Abstract][Full Text] [Related]
20. Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. Lee JY; Schulman MR; Skolnik RA Ann Plast Surg; 2010 Apr; 64(4):435-41. PubMed ID: 20224335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]